Biosimilar Use, Cost Trends In Medicare Part B Will Be Examined By HHS Inspector General

 
• By Cathy Kelly

If study finds biosimilar uptake in the Part B program is lagging, it may inform policy changes to encourage gains. On the other hand,  the latest biosimilars trend reports from Cardinal Health and Amgen show follow-ons are controlling share in some markets for physician-administered drugs and savings are adding up.

magnified money
OIG Will Investigate Extent Of Savings From Biosimilars • Source: Alamy

More from Biosimilars

More from Products